Inactive Instrument

Calendar GALA BIOP Nasdaq

Equities

End-of-day quote Nasdaq
- USD - Intraday chart for GALA BIOP

Chart calendar GALA BIOP

4e6669544ab.SsfAir3nW6fu_CkG3yUMMTDeJfc07wWw8foO88Ph_70.CJCYzdTfY_i6qXBOlnV9S0imbaVhmk_piKh_l5y2mPs5pa_86r4B7Im_bA~e127f46ec8162357c947dd3de3613d5c

Upcoming events on GALA BIOP

2024-05-08 Q1 2024 Earnings Release (Projected)
2024-08-07 Q2 2024 Earnings Release (Projected)
2024-11-13 Q3 2024 Earnings Release (Projected)
2025-03-19 Q4 2024 Earnings Release (Projected)

Past events on GALA BIOP

2024-03-28 04:05 pm Q4 2023 Earnings Release
2024-03-26 08:15 am Business Update Call
2024-03-03 06:00 am European School of Haematology Acute Leukaemias Conference - Abstract No:6192705
2024-01-03 08:30 am Business Update Call
2023-11-23 07:00 am Annual General Meeting
2023-11-09 04:04 pm Q3 2023 Earnings Release
2023-11-04 Global Meeting of the International Gynecologic Cancer Society
2023-09-27 09:10 am Cantor Global Healthcare Conference
2023-08-10 04:08 pm Q2 2023 Earnings Release
2023-06-21 09:30 am Maxim Group Virtual Healthcare Conference - Fireside Chat
2023-06-20 08:30 am Annual General Meeting
2023-06-05 09:00 am American Society of Clinical Oncology Conference - Abstract No : TPS7074
2023-05-30 08:00 am Business Update Call
2023-05-11 04:12 pm Q1 2023 Earnings Release
2023-03-16 04:11 pm Q4 2022 Earnings Release
2023-01-31 08:30 am Investor Meeting - Key Opinion Leader:Galinpepimut-S
2022-12-12 American Society of Hematology Meeting - Abstract #: 4263
2022-12-11 American Society of Hematology Meeting - Abstract #: 3477
2022-12-07 03:20 pm JMP Securities Hematology Oncology Summit
2022-11-14 08:30 am REGAL Phase 3 Clinical Trial Update Call

Annual results

Fiscal PeriodDecember 2019 2020 2021 2022 2023 2024
Net sales
Million USD
Released
Forecast
Spread
0,00
0,00
-
1,90
0,00
-
7,60
5,07
50%
1,00
1,00
0%
0,00
13,0
-

0,00

EBITDA
Released
Forecast
Spread
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-

0,00

EBIT
Million USD
Released
Forecast
Spread
-17,2
-15,7
-9.7%
-17,0
-16,9
-0.39%
-25,3
-24,3
-4.19%
-42,0
-37,7
-11.17%
-37,9
-30,3
-24.83%

-39,3

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-19,4
-14,4
-34.79%
-16,8
-17,2
2.64%
-20,9
-23,4
10.57%
-41,3
-39,6
-4.25%
-37,3
-25,8
-44.54%

-40,0

Net income
Million USD
Released
Forecast
Spread
-28,0
-19,4
-43.97%
-16,8
-17,3
2.41%
-20,7
-21,1
2.04%
-41,3
-39,6
-4.25%
-37,3
-29,8
-25.2%

-40,0

EPS
USD
Released
Forecast
Spread
-10,9
-9,71
-12.52%
-2,11
-1,83
-15.3%
-1,34
-1,34
-0.19%
-2,13
-2,10
-1.55%
-1,34
-1,10
-21.82%

-1,14

Announcement Date13/03/2023/03/2131/03/2216/03/2328/03/24-

Quarterly results

Fiscal PeriodDecember 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales
Million USD
Released
Forecast
Spread
0,00
0,00
-
1,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
0,00
-
0,00
13,0
-
0,00
13,0
-

0,00


0,00


0,00


0,00

EBIT
Million USD
Released
Forecast
Spread
-11,6
-7,03
-65.32%
-6,74
-6,77
0.56%
-8,62
-7,39
-16.66%
-7,15
-8,00
10.71%
-9,45
-7,38
-27.96%
-11,3
-8,56
-31.86%
-8,84
-9,63
8.16%
-9,36
0,70
-1443.52%
-8,18
-0,64
-1168.4%

-10,0


-10,2


-10,4


-10,6

Earnings before Tax (EBT)
Million USD
Released
Forecast
Spread
-6,84
-6,95
1.72%
-16,7
-6,22
-169.41%
-8,41
-7,27
-15.7%
-7,02
-8,00
12.26%
-9,12
-7,17
-27.29%
-11,1
-8,51
-30.36%
-8,84
-9,56
7.49%
-9,27
0,73
-1368.15%
-8,14
3,37
-341.39%

-9,95


-9,96


-10,2


-10,5

Net income
Million USD
Released
Forecast
Spread
-6,60
-6,95
5.12%
-16,7
-6,22
-169.41%
-8,41
-7,27
-15.7%
-7,02
-8,00
12.26%
-9,12
-7,17
-27.29%
-11,1
-8,51
-30.36%
-8,84
-9,56
7.49%
-9,27
0,73
-1368.15%
-8,14
3,37
-341.39%

-9,95


-9,96


-10,2


-10,5

EPS
USD
Released
Forecast
Spread
-0,42
-0,40
-4.13%
-1,05
-0,38
-176.32%
-0,41
-0,39
-5.13%
-0,34
-0,39
12.07%
-0,43
-0,32
-34.38%
-0,47
-0,29
-62.07%
-0,31
-0,36
12.68%
-0,33
0,02
-1985.71%
-0,25
-0,03
-837.38%

-8,13


-0,20


-0,20


-0,19

Announcement Date31/03/2212/05/2211/08/2214/11/2216/03/2311/05/2310/08/2309/11/2328/03/24----